Positron emission tomography with 2-deoxy-2-fluoro-D-glucose integrated with computed tomography (FDG PET/CT) has an established role in the imaging of lymphoma. FDG PET-Magnetic Resonance (FDG PET/MR) is another emerging option. Preliminary results show that whole-body diffusion-weighted MRI has a high sensitivity (90%) and a high specificity (94%), and can be used for the staging of lymphomas with high accuracy [1,2], particularly in small, indolent lymphomas [3]. PET-MR has the added advantage of avoiding radiation exposure, which is especially important in young patients. In general, PET/MRI is likely to be superior to PET/CT where soft tissue contrast is indicated. This image is of an 18 year old male with a diagnosis of Hodgkin’s lym...
Lymphomas are heterogeneous but potentially curable group of neoplasms. Treatment of lymphomas has r...
Computed tomography, 18FDG-PET and the hybrid FDGPET/CT are the most commonly used diagnostic tools ...
The lymphomas comprise approximately 5.0% of all malignancies and are the sixth most frequently occu...
Lymphomas are a heterogeneous group of diseases that arise from the constituent cells of the immune ...
18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) i...
Since the mid-1990s, F-18-fluorodeoxglucose (FDG)-positron emission tomography (PET) in combination ...
Within recent years, F-18 fluorodeoxyglucose (FDG) PET has become the most important nuclear medicin...
Since the mid-1990s, F-18-fluorodeoxglucose (FDG)-positron emission tomography (PET) in combination ...
PET/CT using (18)F-FDG is an essential part of the management of patients with lymphoma. Efforts to ...
Positron emission tomography (PET) is a sectional molecular imaging procedure taht allows evaluation...
Imaging of lymphoma is based on the use of18F-fluorodeoxyglucose positron emission tomography/comput...
Objectives To compare whole body-MRI (WB-MRI) with diffusion-weighted imaging and FDG-PET/CT in stag...
18F-FDG PET/MRI might be the diagnostic method of choice for Hodgkin lymphoma patients, as it combin...
Positron-Emission-Tomography (PET) has emerged as a diagnostic gold standard for most tumor entities...
Malignant lymphomas are a heterogenous group of malignancies, belonging to the ten most frequent typ...
Lymphomas are heterogeneous but potentially curable group of neoplasms. Treatment of lymphomas has r...
Computed tomography, 18FDG-PET and the hybrid FDGPET/CT are the most commonly used diagnostic tools ...
The lymphomas comprise approximately 5.0% of all malignancies and are the sixth most frequently occu...
Lymphomas are a heterogeneous group of diseases that arise from the constituent cells of the immune ...
18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) i...
Since the mid-1990s, F-18-fluorodeoxglucose (FDG)-positron emission tomography (PET) in combination ...
Within recent years, F-18 fluorodeoxyglucose (FDG) PET has become the most important nuclear medicin...
Since the mid-1990s, F-18-fluorodeoxglucose (FDG)-positron emission tomography (PET) in combination ...
PET/CT using (18)F-FDG is an essential part of the management of patients with lymphoma. Efforts to ...
Positron emission tomography (PET) is a sectional molecular imaging procedure taht allows evaluation...
Imaging of lymphoma is based on the use of18F-fluorodeoxyglucose positron emission tomography/comput...
Objectives To compare whole body-MRI (WB-MRI) with diffusion-weighted imaging and FDG-PET/CT in stag...
18F-FDG PET/MRI might be the diagnostic method of choice for Hodgkin lymphoma patients, as it combin...
Positron-Emission-Tomography (PET) has emerged as a diagnostic gold standard for most tumor entities...
Malignant lymphomas are a heterogenous group of malignancies, belonging to the ten most frequent typ...
Lymphomas are heterogeneous but potentially curable group of neoplasms. Treatment of lymphomas has r...
Computed tomography, 18FDG-PET and the hybrid FDGPET/CT are the most commonly used diagnostic tools ...
The lymphomas comprise approximately 5.0% of all malignancies and are the sixth most frequently occu...